Therefore, we investigated the genome-wide methylation status of tumor tissue DNA in patients with metastatic CRC and found that high-methylated CRC (HMCC) cases had a significantly lower response rate to anti-epidermal growth factor receptor (EGFR) therapy compared to low-methylated CRC (LMCC) cases [23]. Here, EGFR is linked to neoplasm.